Skip to main content
SYBX
OTC Life Sciences

Caldera Reports Positive CLD-423 Phase 1a Data, Adds IL-17 x TL1A License Ahead of Synlogic Merger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1
Mkt Cap
$12.249M
52W Low
$0.54
52W High
$1.87
52W Position info
85% above low
Off High info
47% below high
Rel. Volume
Market data snapshot near publication time

SYBX sits 85% above its 52-week low of $0.54.

Summary

Caldera, the private company merging with Synlogic, released positive interim Phase 1a data for its lead bispecific antibody CLD-423, licensed a second IL-17 x TL1A program from Qyuns, and reiterated an upsized ~$278 million concurrent private placement. The merger is still awaiting an effective S-4 and stockholder votes, with closing expected in early 2027.


Key Events · M&A and Partnerships · SYBX

  • CLD-423 Phase 1a Data Positive

    Interim analysis covering the fifth single-dose cohort and both multiple-dose cohorts showed no dose-limiting toxicities, mostly Grade 1 adverse events, an IV half-life above 40 days and approximately 89% subcutaneous bioavailability, with sustained TL1A suppression.

  • Phase 2 IBD Trials Planned for 2027

    Caldera plans a Phase 2b ulcerative colitis trial (IND in Q4 2026, first patient early 2027, induction results by end of 2028) and a Phase 2a Crohn's trial in China (first patient early 2027, initial data late 2027).

  • Qyuns IL-17 x TL1A License Added

    An exclusive worldwide development and commercialization license with Qyuns Therapeutics (HKEX 2509.HK) adds a preclinical bispecific antibody program targeting IL-17 and TL1A; financial terms were not disclosed.

  • Placement Upsized to ~$278M

    Caldera has commitments for an upsized concurrent private placement expected to generate approximately $278 million in gross proceeds from healthcare institutional investors and mutual funds.


Analysis · SYBX · Life Sciences

Synlogic shareholders are being asked to approve an all-stock merger that leaves them with only 2.3% of the combined company, so the value of their stub equity depends almost entirely on Caldera's pipeline. This filing delivers the first substantive clinical update since the deal was struck: CLD-423 was generally well tolerated with no dose-limiting toxicities, showed a half-life above 40 days and roughly 89% subcutaneous bioavailability, and sustained TL1A suppression — enough for Caldera to commit to a Phase 2b ulcerative colitis trial and a Phase 2a Crohn's trial starting in 2027. The Qyuns license adds a second, preclinical bispecific asset at no disclosed cost. The concurrent private placement is now described as upsized to about $278 million, which funds the combined company through those trials. The remaining hurdle is the S-4 registration statement, which has not yet been declared effective, plus stockholder votes at both companies; closing is expected in early 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SYBX was trading at $1.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $0.54 to $1.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYBX - Latest Insights

SYBX
Nov 10, 2026, 7:02 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.9601 info
Change: Low Volume info
Market Cap: $11.76M info
SYBX
Aug 11, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $0.9601 info
Change: Low Volume info
Market Cap: $11.76M info
SYBX
Jul 29, 2026, 7:40 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.9601 info
Change: Low Volume info
Market Cap: $11.76M info
SYBX
Jul 29, 2026, 4:18 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.9601 info
Change: Low Volume info
Market Cap: $11.76M info
SYBX
Jul 29, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.720
Real-time Price: $0.9601 info
Change: Low Volume info
Market Cap: $11.76M info